Physician profile
Daniel Megna
NPI 1235119660
$13,116.29
in general payments reported to CMS, 2019-2025
40 companies · $2,062 in 2025
The $2,062 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,644 · 2020: $1,082 · 2021: $2,075 · 2022: $2,309 · 2023: $2,046 · 2024: $1,898 · 2025: $2,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,819 · Debt Forgiveness: $182 · Education: $5.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,818.78 |
| Debt Forgiveness | $181.83 |
| Education | $5.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,864.79 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,184.62 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,502.63 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $1,053.97 | 2019-2025 | Tremfya, Stelara |
| Celgene Corporation | $849.27 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $643.31 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $430.06 | 2019-2024 | Dificid |
| Pfizer INC. | $371.23 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $349.89 | 2020-2025 | Ocaliva |
| Genzyme Corporation | $306.52 | 2022-2025 | |
| Redhill Biopharma INC. | $293.29 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $246.68 | 2019-2024 | Linzess |
| Lilly USA, LLC | $228.46 | 2023-2025 | Omvoh, Zepbound |
| Olympus America INC. | $224.24 | 2022-2025 | Gastrointestinal Videoscope, Evis Exera III Colonovideoscope |
| Evoke Pharma, INC. | $187.80 | 2021-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Megna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.